Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease.
P P
PP
Sfikakis
P H
PH
Kaklamanis
A
A
Elezoglou
N
N
Katsilambros
P G
PG
Theodossiadis
S
S
Papaefthimiou
N
N
Markomichelakis
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D031300:Retinal Vasculitis / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab